Article Text

Download PDFPDF

#667 Management of endometrial serous carcinoma: a single institute experience
  1. Nayssem Khessairi1,
  2. Lamia Naija1,
  3. Ons Krimi1,
  4. Fatma Saadallah1,
  5. Saida Sakhri1,
  6. Ghada Sahraoui2,
  7. Riadh Chargui1 and
  8. Tarek Ben Dhiab1
  1. 1Surgery department, Salah Azaiez Institute, Tunis, Tunisia
  2. 2Pathology department, Salah Azaiez Institute, Tunis, Tunisia


Introduction/Background Serous endometrial carcinoma is a rare type of endometrial cancer accounting for about 10% of all endometrial neoplasms. It represents an aggressive tumor with a high risk of recurrence and poor prognosis. The management is based on a multimodal treatment combining surgery, chemotherapy, and radiotherapy.

Methodology We conducted a retrospective descriptive study including patients treated for endometrial serous carcinoma who underwent primary surgery at the salah azaiez institute over a period of 10 years from 2011 to 2021.

Results Twenty-five female patients were included in our study. The mean age was 67 years. Metabolic syndrome was found in 54.4% of patients. Clinical examination was normal in 90% of cases. The most frequent tumoral stage was IIIC1(36%). All of our patients underwent primary surgery, which was total hysterectomy and bilateral adnexectomy associated to pelvic lymph node dissection. More than half of patients (54.5%) had omentectomy, and only 36% had paraaortic lymphadenectomy. Regarding post-operative complications, lymphatic issues were the most frequent complications, with 63.6% of patients presenting lower limb lymphedema and 27.3% presenting lymphocele. Furthermore, one patient presented small bowel obstruction by flange and two patients had recto-vaginal fistula. On histologic examination, the average tumour size was 54mm, myometer was invaded in 90.9% of cases, uterine cervix in 72.2% and ovaries in 45.5%. As for nodal involvement, pelvic lymph nodes were invaded in 18.2% of cases and paraaortic lymph nodes in 9% of cases. Ninety-six percent of patients had adjuvant treatment, 54.2% had radio chemotherapy and 18% had brachytherapy. After a median follow-up of 86 months, 45.2% of patients presented locoregional recurrence, and 34.2% are alive with no signs of recurrence.

Conclusion Serous endometrial carcinomas are aggressive and have poor prognosis. Surgical management includes total hysterectomy, bilateral salpingo-oophorectomy, omentectomy and bilateral pelvic lymph node dissection which is considered as an important prognostic factor.

Disclosures None

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.